C4 Therapeutics, Inc.
CCCC · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Anderson Kenneth Carl: Form 4
Insider disclosure · Filed · Report period 01 Oct 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- CCCC · 12529R107 - Common Stock, $0.0001 par value per share
Company details and SEC sources
CIK 0001662579 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- CCCC on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 490 Arsenal Way, Suite 120, Watertown, MA, 02472
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields